Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
CASI Pharmaceuticals Inc. (CASIF) Normalized Income after Taxes data is not available for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Normalized Income after Taxes |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$10.02M |
|
$6.57M |
|
$11.04M |
|
$21.06M |
|
$66.62M |
|
-- |
|
$12.71M |
|
$79.33M |
|
$-58.27M |
|
$-58.48M |
|
$-58.27M |
|
20.56M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|